A phase 1 trial found that CD123-directed CAR T cells are feasible and well-tolerated in patients with relapsed or refractory acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). Investigators reported manageable safety and demonstrated early clinical activity signals as the study continues. CD123 is a therapeutic target expressed on malignant myeloid cells, and CAR strategies have been pursued to deepen responses in aggressive hematologic disease. In this trial, the dataset informs ongoing dose and schedule refinement. For development teams, the practical takeaway is whether CD123 CAR designs can broaden usable options for relapsed patients while maintaining acceptable tolerability in populations where prior treatment histories often heighten risk.
Get the Daily Brief